DrugPatentWatch Database Preview

Daiichi Sankyo Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?

DAIICHI SANKYO INC has six approved drugs.

There are sixteen US patents protecting DAIICHI SANKYO INC drugs.

There are two hundred and eighty-five patent family members on DAIICHI SANKYO INC drugs in forty-five countries and twenty-three supplementary protection certificates in fifteen countries.

Summary for Daiichi Sankyo Inc

International Patents:	285
US Patents:	16
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	9,358,235
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes	7,365,205			Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		RX	Yes	Yes	9,169,250			Y
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No	9,149,532		Y
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	AB	RX	Yes	Yes

Expired US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	4,855,290
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-001	Jul 10, 2009	5,288,726*PED
Daiichi Sankyo Inc	EFFIENT	prasugrel hydrochloride	TABLET;ORAL	022307-002	Jul 10, 2009	5,288,726*PED
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821

Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg and 10 mg		2013-07-10
	Powder for Oral Suspension	1.875 g/Packet and 3.75 g/Packet		2010-04-09
	Tablets	15 mg, 30 mg, 60 mg and 100 mg		2019-01-28
	Tablets	15 mg, 30 mg and 60 mg		2019-01-28
	Tablets	625 mg		2009-07-01
	Capsules	30 mg		2009-02-27

International Patents for Daiichi Sankyo Inc Drugs

Country	Patent Number	Estimated Expiration
China	1509180
South Africa	200903458
World Intellectual Property Organization (WIPO)	2016179415
South Korea	20180015142
Poland	214669
Mexico	2009005428

Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0764174	C300159	Netherlands		PRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310
1405852	CA 2015 00052	Denmark		PRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
0764174	04C0021	France		PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/03/268/001 20040310
1405852	92835	Luxembourg		PRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619
1405852	300760	Netherlands		PRODUCT NAME: EDOXABAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOXABAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993 20150619
1405852	132016000024022	Italy		PRODUCT NAME: EDOXABAN, UN SUO SALE, UN SUO SOLVATO O UN SUO N-OSSIDO, IN PARTICOLARE EDOXABAN TOSILATO(LIXIANA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/993/001-028, 20150623

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Daiichi
• Daiichi Sankyo
• Daiichi Sankyo Inc